BCX 1170

Drug Profile

BCX 1170

Latest Information Update: 25 Jan 2005

Price : $50

At a glance

  • Originator BioCryst Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Complement C1 inhibitors; Complement factor D inhibitors; Serine endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Inflammation

Most Recent Events

  • 25 Jan 2005 Discontinued - Preclinical for Inflammation in USA (unspecified route)
  • 27 Apr 2001 No-Development-Reported for Inflammation in USA (Unknown route)
  • 03 Sep 1998 Preclinical development for Inflammation in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top